Skip to main content

Table 3 Therapeutic regimen of 150 patients with cryptococcal meningitis

From: The utility of cerebrospinal fluid white cell count during the prognostic assessment for cryptococcal meningitis patients: a retrospective study

Treatment All (N = 150)
(n,%)
Good outcome (N = 94)
(n,%)
Bad outcome (N = 56)
(n,%)
P-value
No treatment 16 (10.67) 0 (0.00) 16 (28.57) 0.000
Monotherapy 11 (7.33) 3 (3.19) 8 (14.29)
Two-drug combination 81 (54.00) 54 (57.45) 27 (48.21)
Triple therapy 42 (28.00) 37 (39.36) 5 (8.93)
Antifungal treatment
 AmB 9 (6.00) 3 (3.19) 6 (10.71) 0.079
 FCZ 2 (1.33) 0 (0.00) 2 (3.57) 0.138
 AmB +  5FC 59 (39.33) 40 (42.55) 19 (33.93) 0.296
 AmB + FCZ 9 (6.00) 4 (4.26) 5 (8.93) 0.295
 AmB + VCZ 3 (2.00) 1 (1.06) 2 (3.57) 0.556
 FCZ +  5-FC 4 (2.67) 3 (3.19) 1 (1.79) 1.000
 VCZ +  5-FC 6 (4.00) 6 (6.38) 0 (0.00) 0.084
 AmB + FCZ+  5-FC 15 (10.00) 13 (13.83) 2 (3.57) 0.050
 AmB + VCZ+ 5-FC 27 (18.00) 24 (25.53) 3 (5.36) 0.002
  1. AmB amphotericin B, FCZ fluconazole, VCZ voriconazole, 5-FC 5-flucytosine